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To the Editor: A healthy 37-year-old woman with no eye disorders 
or prior eye surgery climbed from 1 980 m to 5  681 m on 
Kilimanjaro. She took acetazolamide, a carbonic anhydrase inhibitor, 
as prophylaxis against acute mountain sickness. She had no mountain 
sickness, but developed progressive painless blurred vision during 
her summit attempt on day 5. Her husband noted that her eyes looked 
opaque. 
She descended to a local hospital. On ophthalmological 
examination 22 hours after beginning the descent her vision was 
improving, to 6/18 in the right eye and 6/24 in the left eye. There 
were superficial punctate lesions in the lower third of one cornea, 
consistent with minor abrasions from flying volcanic dust. Folds in 
Descemet’s membrane suggested corneal oedema. The findings on 
fundal examination appeared normal, although visualisation was 
poor. Intra-ocular pressures were 13 mmHg in both eyes.
Twelve hours later, vision had improved to 6/9 and 6/12 and 
folding of Descemet’s membrane had lessened. Visual impairment 
resolved over 2 days. 
Follow-up examination several weeks later in Johannesburg was 
unremarkable. The anterior chamber was normal. Central corneal 
thickness was normal, 0.535 mm in the right eye and 0.543 mm in the left 
eye. A subsequent endothelial analysis showed a typical endothelial cell 
density, 2 537/mm2 in the right eye and 2 555/mm2 in the left eye. Central 
corneal thickness was unchanged from the previous examination.
The corneal endothelium is a thin-cell monolayer at the posterior 
surface of the cornea, facing the anterior chamber of the eye. It 
regulates corneal hydration by various active transport mechanisms, 
causing water flow from out of the stroma into the anterior chamber.1 
Endothelial oxygen supply is predominantly by transcorneal diffusion 
from the atmosphere. Impairment of endothelial oxygenation impairs 
fluid transport and promotes corneal oedema. 
The decrease in the partial pressure of atmospheric oxygen during 
rapid high-altitude ascent is associated with mild, asymptomatic 
corneal swelling.2,3 This oedema decreases as the endothelium adapts 
to the hypoxic environment. In the normal eye, the endothelium’s 
adaptive reserve is probably sufficient to ensure that the severity and 
rate of hypoxic exposure typically experienced by climbers do not 
produce clinically significant problems. To our knowledge, there are 
no reports of high-altitude corneal oedema producing symptoms in 
previously healthy climbers. 
Visual impairment due to high-altitude corneal oedema in 
association with other factors has occasionally been reported, 
however.4,5 Symptomatic hyperopic shift may occur in persons who 
have had prior radial keratotomy, which alters the cornea’s refractive 
state.4 Another suggested mechanism is reduced endothelial function, 
such as occurs in Fuchs’ corneal dystrophy. In a 77-year-old man 
who developed corneal oedema after a rapid ascent to 3 800 m, the 
limited adaptive reserve of the diseased endothelium to hypoxia was 
suggested to have caused the decompensation.5  
In the current patient, with a normal endothelium and no prior 
surgery, acetazolamide may have contributed to the marked corneal 
oedema by impairing the endothelial adaption to hypoxia. Carbonic 
anhydrase pumps are important endothelial pumps regulating fluid 
movement.1 Acetazolamide, a carbonic anhydrase inhibitor, produces 
corneal swelling by inhibiting these pumps. We suggest that oral 
acetazolamide may have produced sufficient endothelial inhibition, 
while simultaneously facilitating ascent by reducing symptoms of 
mountain sickness, to produce symptomatic oedema.
One other similar case has been reported.6 A climber taking oral 
acetazolamide developed high-altitude pulmonary oedema, blurred 
vision and myopia without other neurological symptoms at 4 700 m. 
Both visual and pulmonary symptoms resolved with descent. The 
findings on subsequent eye examination were normal. We speculate 
that, as in our case, carbonic anhydrase inhibition of the endothelium 
may have been the mechanism of visual impairment.  
Fast ascent can cause acute mountain sickness and high-altitude 
cerebral or pulmonary oedema, symptoms of which may mask 
coexistent corneal oedema. As most high mountains are in remote, 
sparsely populated ranges, visual abnormalities may resolve by 
the time climbers descend to a large hospital to obtain a formal 
examination. Kilimanjaro, a volcano, is a large freestanding mountain 
rising above a well-populated plain. The fortuitous combination of 
a nearby specialist hospital, a very rapid descent and the absence 
of other high-altitude symptoms allowed for this condition to be 
diagnosed. Symptomatic high-altitude corneal oedema may therefore 
be more common than is realised, but resolve before examination 
takes place, or the symptoms may erroneously be attributed to one of 
the high-altitude syndromes.
Myopia and endothelial dysfunction are rare adverse reactions 
to acetazolamide. Since oral acetazolamide is typically taken as 
prophylaxis before and during a rapid ascent, these side-effects 
could coincide with altitude gain. While the current report cannot 
demonstrate whether the association with ascent was causal or 
simply contemporaneous, acetazolamide-related complications may 
therefore occur during climbing.
Given the frequent use of acetazolamide to facilitate rapid climbs, the 
major increase in adventure tourism, and the life-threatening consequences 
of visual impairment on high mountains, this unusual complication should 
be recognised. If visual changes occur at altitude, the climber should stop 
taking acetazolamide and consider immediate descent.
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